Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study
Multiple Sclerosis Journal · 2024
DOI: 10.1177/13524585241238136 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Multiple Sclerosis Journal, 2024. Verfasst von Fabrizia Mealli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics Informatics and Applications 'Giuseppe Parenti', University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Administration, Intravenous, Natalizumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
To quantify the probability that monthly intravenous (IV) and subcutaneous (SC) natalizumab (NTZ) had similar efficacy in relapsing-remitting multiple sclerosis (RRMS), non-inferiority of efficacy of NTZ-SC versus NTZ-IV on combined MRI unique active lesions number (CUAL) was explored re-analysing the REFINE data set. Non-inferiority margins were selected equal to 25%/33%/50% fractions of the effect size of NTZ-IV versus placebo observed in the AFFIRM study. Ninety-nine RRMS were included. NTZ-SC resulted not inferior to NTZ-IV on CUAL for all margins at 2.5% significance level, and, in worst-case scenario, its effect over NTZ-IV did not exceed 3.5% (or 2.8%) of the effect of NTZ-IV versus placebo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Statistics Informatics and Applications 'Giuseppe Parenti', University of Florence, Florence, Italy.
- Florence Centre for Data Science, Florence, Italy.
- Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy.
- Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy.
ORCID-Profile: Alice Mariottini
Zitieren
APA
Mealli, F., Mattei, A., Mariottini, A., & Massacesi, L. (2024). Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241238136
Vancouver
Mealli F, Mattei A, Mariottini A, Massacesi L. Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241238136
BibTeX
@article{Mealli2024,
author = {Mealli, Fabrizia and Mattei, Alessandra and Mariottini, Alice and Massacesi, Luca},
title = {Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study},
journal = {Multiple Sclerosis Journal},
year = {2024},
doi = {10.1177/13524585241238136}
}
EUVIMED